Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4GWL7)

Drug Name

Gefapixant Drug Info

Synonyms

UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid

Indication

Disease Entry	ICD 11	Status	REF
Cough	MD12	Phase 3	[1]
Overactive bladder	GC50.0	Phase 2	[2]

Cross-matching ID

PubChem CID: 24764487
CAS Number: CAS 1015787-98-0
TTD Drug ID: DM4GWL7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2X purinoceptor 3 (P2RX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY-1902607	DMYSQMW	Cough	MD12	Phase 2	[1]
BAY 1902607	DMFA4CK	Cough	MD12	Phase 1/2	[1]
AF-130	DM8LG2I	Hypertension	BA00-BA04	Phase 1	[3]
BAY-1817080	DMNL5G7	Endometriosis	GA10	Phase 1	[1]
BAY 1817080	DMF9ALP	Cough	MD12	Phase 1	[4]
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[5]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[6]
ISOPPADS	DMWI0M8	Discovery agent	N.A.	Investigative	[7]
LVAYPWT	DMIO405	Discovery agent	N.A.	Investigative	[8]
MK-3901	DM5EQ7F	Pain	MG30-MG3Z	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 3 (P2RX3)	TT2THBD	P2RX3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2	ClinicalTrials.gov (NCT02477709) A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
6	Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
7	Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
8	Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.